Despite the significant potential and advantages of GLP-1RAs, they are inevitably accompanied by a range of possible adverse drug reactions (ADRs), as is the case with any medication
M., Rot, M
Tirzepatide was found to dose-dependently reduce levels of apolipoprotein (apo) B and apoC-III, increase serum lipoprotein lipase (LPL), and decrease large triglyceride-rich lipoprotein particles (TRLP) and small low-density lipoprotein particles (LDLP) in the volunteers
Appetite suppression and metabolic effects taper over 4 to 5 weeks rather than stopping abruptly
"GLP-1 medications can increase the risk of dehydration because you may drink less, experience nausea or develop vomiting or diarrhea," Duah says
New analysis of GLP-1 drugs suggests people who stopped using medications regained 60% of weight lost A new study, recently shared on Good Morning America , on life after weight loss drugs examined 48 studies that analyzed and predicted the outcomes of people who either had diabetes or were overweight or obese and took popular GLP-1 medications